PDE10A Inhibition in Schizophrenia: A Randomised, Placebo-Controlled Phase 2 Study of Alofropodect (CPL’36) in Patients Experiencing Acute Schizophrenia
CNS Drugs · 2026-09 · 40 (9) · 1295-1305
DOI: 10.1007/s40263-026-01317-5 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift CNS Drugs, online erschienen am 31.07.2026. Verfasst von Maciej Wieczorek und 12 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development Centre, Celon Pharma S.A., Kazuń Nowy, Poland. Hauptthemen laut MEDLINE: Schizophrenia, Antipsychotic Agents, Phosphoric Diester Hydrolases, Phosphodiesterase Inhibitors. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Narodowe Centrum Badań i Rozwoju.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research and Development Centre, Celon Pharma S.A., Kazuń Nowy, Poland.
- Department of Psychiatry, Medical University of Białystok, Białystok, Poland.
- Provincial Psychiatric Health Hospital named after Dr Józef Bednarz in Świecie, Świecie, Poland.
- Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary.
- Department of Psychiatry, Narcology and Medical Psychology, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine.
- Lviv Regional Clinical Psychiatric Hospital, Lviv, Ukraine.
ORCID-Profile: Maciej Wieczorek, Napoleon Waszkiewicz, János M Réthelyi, Mykhaylo Pustovoyt, Yuriy Filts, Yuliya Blazhevych, Mikołaj Matłoka, Barbara Łapińska, Piotr J Rudzki, Radosław Jaźwiec
Förderung
- Narodowe Centrum Badań i Rozwoju
Zitieren
APA
Wieczorek, M., Waszkiewicz, N., Gromniak-Haniecka, E., Réthelyi, J. M., Pustovoyt, M., Filts, Y., Blazhevych, Y., Matłoka, M., Janowska, S., Łapińska, B., Rudzki, P. J., Jaźwiec, R., & Sierzputowska-Prarat, J. (2026). PDE10A Inhibition in Schizophrenia: A Randomised, Placebo-Controlled Phase 2 Study of Alofropodect (CPL’36) in Patients Experiencing Acute Schizophrenia. CNS Drugs, 40(9), 1295-1305. https://doi.org/10.1007/s40263-026-01317-5
Vancouver
Wieczorek M, Waszkiewicz N, Gromniak-Haniecka E, Réthelyi JM, Pustovoyt M, Filts Y, et al. PDE10A Inhibition in Schizophrenia: A Randomised, Placebo-Controlled Phase 2 Study of Alofropodect (CPL’36) in Patients Experiencing Acute Schizophrenia. CNS Drugs. 2026;40(9):1295-1305. doi:10.1007/s40263-026-01317-5
BibTeX
@article{Wieczorek2026,
author = {Wieczorek, Maciej and Waszkiewicz, Napoleon and Gromniak-Haniecka, Ewa and Réthelyi, János M and Pustovoyt, Mykhaylo and Filts, Yuriy and Blazhevych, Yuliya and Matłoka, Mikołaj and Janowska, Sylwia and Łapińska, Barbara and Rudzki, Piotr J and Jaźwiec, Radosław and Sierzputowska-Prarat, Joanna},
title = {PDE10A Inhibition in Schizophrenia: A Randomised, Placebo-Controlled Phase 2 Study of Alofropodect (CPL’36) in Patients Experiencing Acute Schizophrenia},
journal = {CNS Drugs},
year = {2026},
volume = {40},
number = {9},
pages = {1295--1305},
doi = {10.1007/s40263-026-01317-5}
}
EUVIMED